The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology

Panminerva Medica

Volumn 54, Issue 4, 2012, Pages 305-312

  Mauro, M ^a   Incorvaia, C ^b   Formigoni, C ^a   Elia, R ^b   Russello, M ^a   Pellegrino, D ^a  

^a SANT ANNA HOSPITAL   (Italy)

^b Istituti Clinici di Perfezionamento   (Italy)

Author keywords

Anaphylaxis; Anti IgE; Asthma; Dermatitis, atopic; Food hypersensivity; Omalizumab; Rhinitis

Indexed keywords

ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB;

BLOOD; DRUG EFFECT; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; OFF LABEL DRUG USE; PRACTICE GUIDELINE; REVIEW; SIGNAL TRANSDUCTION;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; OFF-LABEL USE; PRACTICE GUIDELINES AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84871536831     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Siraganian RP. Mechanisms of IgE-mediated hypersensitivity. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. Allergy. Principles and practice. St. Louis: Mosby; 1993. p. 105-34.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
3. Jardieu PM, Fick RBJ. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999;118:112-5. (Pubitemid 29195481)
4. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001; 164: S6-11.
5. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA et al. Omalizumab rapidly decreases nasal allergic response and FCeRI on basophils. J Allergy Clin Immunol 2004; 113:297-302. (Pubitemid 38210553)
6. Spector S. Omalizumab: efficacy in allergic disease. Panminerva Med 2004;46:141-8. (Pubitemid 39523923)
7. Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T et al. American academy of allergy, asthma and immunology/ American college of allergy, asthma and immunology omalizumab-associated anaphylaxis joint task force follow-up report. J Allergy Clin Immunol 2011; 128: 210-2.
8. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev Apr 2006; 19: CD003559.
9. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The Persist study. Respir Med 2009; 103: 1633-42.
10. Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A et al. Italian real-life experience of omalizumab. Respir Med May 2010; 104: 1410-6.
11. Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin 2010; 26: 1285-93.
12. Johansson SG, Nopp A, Oman H, Ankerst J, Cardell LO, Grönneberg R et al. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009; 64: 1472-7.
13. Nopp A, Johansson SG, Adédoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; A 3-year withdrawal follow-up. Allergy 2010; 65: 56-60.
14. Rabe KF, Calhoun WJ, Smith N, Jimenez P. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 2011; 66: 1142-51.
15. Barnes PJ. Intrinsic asthma: Not so different from allergic asthma but driven by superantigens? Clin Exp Allergy 2009; 39: 1145-51.
16. Marone G, Rossi FW, Detoraki A, Granata F, Marone G, Genovese A et al. Role of superallergens in allergic disorders. Chem Immunol Allergy 2007;93:195-213. (Pubitemid 46924879)
17. Luskova P, Draber P. Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors. Search for therapeutic targets of inflammatory and allergy diseases. Curr Pharm Des 2004;10:1727-37. (Pubitemid 38647455)
18. Zaidi AK, Saini SS, Macglashan DW Regulation of Syk kinase and FcRbeta expression in human basophils durinf treatment with omalizumab. J Allergy Clin Immunol 2010; 125: 902-6.
19. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M et al. Omalizumab Seasonal Allergic Rhinitis Trial Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956-67. (Pubitemid 33140359)
20. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, FowlerTaylor A et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-7. (Pubitemid 36999475)
21. Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: Patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009; 64: 81-4.
22. Moriaria JB, Polosa R. Off-label use of omalizumab in non-asthma conditions: New opportunitites. Expert Rev Respir Med 2009; 3: 299-308.
23. Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis - and eventually nasal polyps? Int Arch Allergy Immunol 2009; 148: 87-98.
24. Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007;21:428-32. (Pubitemid 47360029)
25. Guglielmo M, Gulotta C, Mancini F, Sacchi M, Tarantini F. Recalcitrant nasal polyposis: Achievement of total remission following treatment with omalizumab. J Invest Allergol Clin Immunol 2009; 19: 158-9.
26. Incorvaia C, Mauro M, Riario-Sforza GG, Frati F, Tarantini F, Caserini M. Current and future applications of the anti-IgE antibody omalizumab. Biologies 2008; 2: 67-73.
27. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study. Allergy Asthma Proc 2008; 29: 530-7.
28. Ramírez del Pozo ME, Contreras Contreras E, López Tiro J, Gómez Vera J. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 2011; 21: 416-7.
29. Toledo F, Silvestre JF, Muñoz C. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic der matitis. Report of four cases. J Eur Acad Dermatol Venereol 2011 Nov 3 [Epub ahead of print]
30. Boyce JA. Successful treatment of cold-induced urticaria/anaphy laxis with anti-IgE. J Allergy Clin Immunol 2006;117:1415-8. (Pubitemid 43795744)
31. Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy 2010; 65: 931-2.
32. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010; 65: 138-9.
33. Güzelbey O, Ardelean E, Magert M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 1563-5.
34. Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010; 125: 490-1.
35. Duchini G, Bäumler W, Bircher AJ, Scherer K. Failure of omalizumab (Xolair) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 2011; 27: 336-7.
36. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 247-9.
37. Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol 2010; 35: 127-9.
38. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007;120:979-81. (Pubitemid 47534214)
39. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99:190-3. (Pubitemid 47264781)
40. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with Hl-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 128: 567-73.
41. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569-73.
42. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S et al. Efficacy and safety of omalizumab in patients with chronic Urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128; 202-9.
43. Siebenhaar F, Kühn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 2007;120:213-5. (Pubitemid 46990509)
44. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119:1550-1. (Pubitemid 46855867)
45. Rueff F, Dugas-Breit S, Przybilla B. Stinging hymenoptera and mastocytosis. Curr Opin Allergy Clin Immunol 2009; 9: 338-42.
46. Kontou-Fili K, Fili CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009; 64: 1384-5.
47. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O'Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a non atopic patient. Allergy 2010; 65: 926-7.
48. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001;107:191-3. (Pubitemid 32105265)
49. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH et al. Avon longitudinal study of parents and children study team. effects of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348: 975-6.
50. Jones JD, Mamey SR Jr, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 2008; 101: 550-1.
51. Warner P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009; 102: 257-8.
52. National Institute of Allergy and Infectious Diseases (NIAID). ClinicalTrials.gov NCT00890162.
53. Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W. Effects of omalizumab in patients with food allergy, Allergy Asthma Proc 2010; 31: 76-83.
54. Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007;120:594-601. (Pubitemid 47320766)
55. Foster B, Foroughi S, Yin Y, Prussin C. Effects of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders. Clin Mol Allergy 2011; 28: 1-7.
56. Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc 2010; 7: 237-44.
57. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007;62:276-7. (Pubitemid 46579813)
58. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43: 1249-51.
59. Lin RY, Sethi S, Bhargave GA. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. J Asthma 2010; 47: 942-5.
60. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008;43:607-10. (Pubitemid 351813015)
61. Brinkmann F, Schwerk N, Hansen G, Ballmann M. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010; 65: 134-5.
62. Pérez-de-Llano LA, Vennera MC, Parra A, Guallar J, Marin M, Asensio O, Ausin P, Borderías L, Fernández C, Granel C, Pérez-Pimiento A, Rubio M. Effects of omalizumab in aspergillus- associated airway disease. Thorax 2011; 66: 539-40.
63. Agarwal R. Severe asthma with fungal sensitization. Curr Allergy Asthma Rep 2011; 11: 403-13.
64. Incorvaia C, Frati F, Puccinelli P, Riario-Sforza GG, Dal Bo S. Dose dependence of efficacy and safety of subcutaneous immunotherapy. Monaldi Arch Chest Dis 2006;65:41-3. (Pubitemid 43676459)
65. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125: 383-9.
66. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010; 21( 1 Pt2): el60-5.
67. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al. DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39: 271-9.
68. Müller UR, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89: 529-34.
69. Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007;62:963-4. (Pubitemid 47037850)
70. Rerinck HC, Rueff F, Przybilla B. Recurrent severe anaphylactic reactions to venom immunotherapy (VIT): Omalizumab induces tolerance. J Allergy Clin Immunol 2008;( suppl 29: 111.
71. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: Efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19: 225-9.
72. Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 2008;18:225-6. (Pubitemid 351872293)